[A24-82] Nirsevimab (secondary prophylaxis of RSV lower respiratory tract disease, 2nd. RSV season) – Benefit assessment according to §35a Social Code Book (SGB) V
Last updated 15.11.2024
Project no.:
A24-82
Commission:
Commission awarded on 15.08.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Therapeutic indication: Children ≤ 24 months of age during their 2nd RSV season with indication for secondary prophylaxis of lower respiratory tract infections caused by respiratory syncytial virus
- Children in whom palivizumab is indicated: added benefit not proven
- Children in whom palivizumab is not indicated: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A24-82_en
| Project no. | Title | Status |
|---|---|---|
| A24-27 | Nirsevimab (prevention of RSV disease) – Benefit assessment according to §35a Social Code Book V | Commission completed |